Financial Performance - Q4 2025 revenues reached $13.4 million, marking a 29.7% increase from Q4 2024, and setting an all-time quarterly record for the company [1][5] - Full year 2025 revenues totaled $44.1 million, a 35.0% increase from $32.6 million in 2024, also an all-time annual record [1][11] - Q4 2025 gross margin was 74.7%, down from 77.9% in Q4 2024, while full year 2025 gross margin improved to 77.1% from 75.2% in 2024 [1][5][11] - GAAP Operating Income for Q4 2025 was $2.0 million, unchanged from Q4 2024, and full year operating income was $4.9 million, an increase of $1.1 million compared to 2024 [1][5][11] Product Sales and Market Dynamics - A total of 255 UltraMist® systems were sold in Q4 2025, up from 135 in Q4 2024 and 155 in Q3 2025 [5] - UltraMist® consumables revenue increased by 10.6% to $6.5 million in Q4 2025, representing 48.7% of overall revenues [5] - The UltraMist® systems and consumables accounted for approximately 100% of the company's overall revenues in Q4 2025 [5] - The company noted a shift in the wound care market due to changes in CMS reimbursement policies, leading to both challenges and opportunities for growth [7] Future Guidance - The company provides guidance for Q1 2026 revenues of $9.6 to $10.3 million, indicating a 3-10% increase compared to Q1 2025 [2][8] - Full year 2026 revenue guidance is set at $51.0 to $55.0 million, reflecting a growth of 16-25% compared to 2025 [2][8]

Core Insights - Calian Group Ltd. has exercised $75 million of its accordion feature, increasing total committed capacity under its credit facility to $275 million [2] - The company renewed its credit facility on September 29, 2025, for a three-year term with a total capacity of $350 million [2] - As of December 31, 2025, Calian had $165 million drawn on the facility and a net debt to adjusted EBITDA ratio of 1.2x [2] Financial Position - The increase in credit capacity strengthens Calian's ability to pursue acquisitions and invest in organic growth opportunities [3] - The company has a robust backlog of $1.4 billion, positioning it well to deploy capital strategically [3] Leadership Changes - Derek Clark, President of the Essential Industries business unit, is leaving the company for a new opportunity [3] - The Essential Industries business will continue to be supported by a strong leadership team during the transition [3][4]

Core Insights - KULR Technology Group, Inc. will hold a conference call on March 31, 2026, to discuss its financial results for Q4 and the full year ended December 31, 2025 [1][3] - The financial results will be released in a press release prior to the call [1] - Interested parties can submit questions to management before the call, which will be addressed based on relevance and appropriateness [2] Company Overview - KULR Technology Group designs and builds advanced battery systems for various applications including autonomous platforms, digital infrastructure, e-mobility, and spaceflight [4] - The company operates through four revenue engines: KULR ONE hardware, Energy-as-a-Service subscription, Dual-Life battery lifecycle model, and an on-chain AI agent intelligence layer [4]

Core Viewpoint - XORTX Therapeutics Inc. has delayed its share consolidation from March 27, 2026, to April 6, 2026, pending necessary approvals from the TSX Venture Exchange and Nasdaq Stock Exchange [1] Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease [2] - The company has three clinically advanced products: 1. XRx-026 for gout treatment 2. XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) 3. XRx-101 for acute kidney injury related to respiratory virus infections - Additionally, XORTX is developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy [2] - The company aims to target aberrant purine metabolism and xanthine oxidase to reduce uric acid production [2]

Core Viewpoint - Disc Medicine, Inc. has completed enrollment in the Phase 3 APOLLO trial for bitopertin, which targets erythropoietic protoporphyria (EPP), expanding the study size to 183 participants due to high demand [1][7]. Group 1: Study Details - The APOLLO trial is a double-blind, placebo-controlled study involving patients aged 12 and above, with sites in the US, Canada, Europe, and Australia [2]. - Co-primary endpoints include average monthly total time in sunlight without pain and percent change in whole blood metal-free PPIX after 6 months of treatment [2]. - Results from the APOLLO study are expected in Q4 2026, with a complete response letter (CRL) to be submitted to the FDA, and a decision anticipated by mid-2027 [2][7]. Group 2: About Bitopertin - Bitopertin is an investigational, orally administered inhibitor of glycine transporter 1 (GlyT1), aimed at modulating heme biosynthesis and supporting erythropoiesis [3]. - It is being developed as a potential first disease-modifying therapy for erythropoietic porphyrias [3]. - The drug has undergone multiple clinical trials, including the Phase 2 BEACON and AURORA trials, and the ongoing Phase 3 APOLLO trial [3]. Group 3: Company Overview - Disc Medicine is focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases, targeting heme biosynthesis and iron homeostasis [5]. - The company aims to build a portfolio of innovative therapeutic candidates to address a wide spectrum of hematologic diseases [5]. - Disc obtained global rights to bitopertin from Roche in May 2021 [4].

Merger Announcement - CVB Financial Corp and Heritage Commerce Corp have announced that their shareholders have approved the proposed merger, with Heritage Commerce Corp merging into CVB Financial Corp [1][2] Regulatory Approval and Timeline - The merger is subject to regulatory approvals and other closing conditions, with an anticipated completion in the second quarter of 2026 [2] Company Profiles - CVB Financial Corp is a publicly traded holding company for Citizens Business Bank, with over $15 billion in total assets and recognized as one of the top performing banks in the nation [3] - Heritage Commerce Corp is a publicly traded holding company for Heritage Bank of Commerce, offering a range of commercial and personal banking services, and is rated as one of the nation's strongest financial institutions [4]

Core Viewpoint - PyroGenesis Inc. has successfully closed a non-brokered private placement, raising gross proceeds of $1,973,450 by selling 3,654,537 units at a price of $0.54 per unit, which was oversubscribed [1][2]. Group 1: Private Placement Details - The private placement was initially structured to raise approximately $1,000,000 through the issuance of up to 1,851,852 units [2]. - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at a price of $0.70 for 36 months [2]. - The common shares and warrants issued will be subject to a statutory hold period of four months and one day from the closing date [2]. Group 2: Insider Participation - P. Peter Pascali, the President and CEO of PyroGenesis, subscribed for approximately $400,000, which is the maximum amount allowed for insiders under current regulations [4]. Group 3: Use of Proceeds - The company intends to use the net proceeds from the private placement for working capital and general corporate purposes [5]. Group 4: Regulatory Approval - The private placement has been conditionally approved by the TSX but remains subject to final approval and other customary closing conditions [5]. Group 5: Company Overview - PyroGenesis leverages 35 years of plasma technology leadership to provide advanced engineering solutions across various industries, including energy, defense, and heavy industry [7]. - The company is ISO 9001:2015 and AS9100D certified, maintaining ISO certification since 1997 [7].

Core Insights - Inspira Technologies has transitioned from clinical validation to early commercial execution in 2025, with significant progress in commercialization pathways for the INSPIRA™ ART100 system [2] - The company reported initial revenues of approximately $289,000 for the year ended December 31, 2025, primarily from the ART100 system [6] - Inspira is focused on expanding its clinical and commercial deployment while converting its growing opportunity base into revenue throughout 2026 [2] Business and Operational Highlights - The ART100 system was successfully used in clinical procedures at leading medical centers, including lung transplants, marking a critical milestone in its clinical performance [3] - The company received vendor approval for the ART100, allowing it to enter formal procurement pathways across a major healthcare network [3] - Inspira appointed Mike Hershkovitz as Vice President of Global Sales to support its expansion efforts [4] Financial Performance - Research and development expenses increased to $7,496,000 in 2025 from $6,323,000 in 2024, primarily due to higher share-based compensation and exchange rate fluctuations [7] - General and administrative expenses rose to $5,532,000 in 2025 from $4,185,000 in 2024, driven by higher salary expenses and share-based compensation [8] - The net loss for the year ended December 31, 2025, was $13,220,000, compared to a loss of $11,053,000 in 2024 [10] Cash Position and Liquidity - Cash and cash equivalents totaled $3,159,000 as of December 31, 2025, down from $5,779,000 in 2024 [11] - The company completed a registered direct offering generating approximately $4.75 million in gross proceeds, enhancing its liquidity position [11] Strategic Evaluation - Inspira entered into a non-binding term sheet with Bio-View Ltd. for a proposed acquisition but later decided not to proceed with the transaction [5] - The company is currently evaluating strategic alternatives to generate significant shareholder value [5]

Company Overview - Abundia Global Impact Group, Inc. (NYSE American: AGIG) is a low-carbon energy company focused on converting waste into value, specifically waste plastics and biomass into drop-in fuels and low-carbon chemical feedstocks [3] Annual Meeting Announcement - The 2026 Annual Meeting of Stockholders (AGM) is scheduled for May 14, 2026, at 11:00 a.m. Central Daylight Time, with meeting materials to be available around April 3, 2026 [1] Financial Reporting - The audited consolidated financial statements for the fiscal year ended December 31, 2025, include an audit report with a going concern qualification, as required by Section 610(b) of the NYSE American Company Guide [2]

Core Viewpoint - Kornit Digital LTD. has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC, which includes audited financial statements [1] Company Overview - Kornit Digital is a global leader in sustainable, on-demand digital fashion and textile production technologies, offering end-to-end solutions including digital printing systems, inks, consumables, software, and fulfillment services [3] - The company is headquartered in Israel and has offices in the USA, Europe, and Asia Pacific, serving customers in over 100 countries [3] Investor Relations - Shareholders can request a hard copy of the annual report on Form 20-F, including complete audited financial statements, free of charge [2] - The contact for investor relations is Andrew Backman, Chief Capital Markets Officer [4]